X @Bloomberg
Bloomberg·2025-11-17 12:48
Market Strategy - Novo Nordisk is undercutting Eli Lilly on obesity drugs for cash-pay patients [1] - The company aims to regain a larger share of the US market [1]
Market Strategy - Novo Nordisk is undercutting Eli Lilly on obesity drugs for cash-pay patients [1] - The company aims to regain a larger share of the US market [1]